Chronic Lymphocytic Leukemia | Specialty

Efficacy and Future Role of Ibrutinib in CLL and MCL

January 22nd 2014

Surrogate Endpoints for New Drug Discovery in ALL

January 22nd 2014

Emerging Strategies in the Treatment of ALL

January 22nd 2014

Novel Therapies for Patients Ph-Negative ALL

January 22nd 2014

Introduction: Treating ALL in Adult Patients

January 22nd 2014

Dr. Byrd Provides an Update on Ibrutinib in CLL

January 2nd 2014

John C. Byrd, MD, from The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), provides an update on ibrutinib for the treatment of CLL.

Idelalisib Improves Survival in High-Risk CLL

December 13th 2013

Combination treatment with idelalisib plus rituximab was associated with a >70% improvement in OS in patients with high-risk relapsed/refractory CLL.

Latest Data Further Support Ibrutinib's Efficacy in CLL

December 11th 2013

Several trials of ibrutinib, an oral BTK inhibitor, either alone or in combination with currently used therapies for patients with chronic lymphocytic leukemia were presented at the 55th Annual Meeting of the American Society of Hematology.

Dr. Furman on Avoiding Chemotherapy With Idelalisib

December 10th 2013

Richard R. Furman, MD, from the New York Weill Cornell Medical Center, discusses the ability to avoid the administration of chemotherapy when using novel agents, such as idelalisib, to treat patients with chronic lymphocytic leukemia.

Ofatumumab Improves Response Rates, PFS in Elderly/Unfit Patients With CLL

December 10th 2013

Adding ofatumumab to chlorambucil in patients with previously untreated chronic lymphocytic leukemia who are considered inappropriate for fludarabine improves clinical outcomes and is tolerable irrespective of patient age or fitness.

Dr. Flinn Discusses the Efficacy of IPI-145 in CLL

December 9th 2013

Ian W. Flinn, MD, PhD, from the Sarah Cannon Research Institute, discusses the preliminary efficacy of IPI-145 in patients with chronic lymphocyic leukemia (CLL).

IPI-145 Has Activity in Relapsed/Refractory CLL

December 9th 2013

Almost half of patients with relapsed or refractory chronic lymphocytic leukemia attained objective responses when treated with an oral inhibitor of phosphoinositide-3-kinase-delta and -gamma.

Bcl-2 Inhibitor ABT-199 Shows Promise in CLL and SLL

December 9th 2013

ABT-199, an orally bioavailable selective inhibitor of the Bcl-2 protein as monotherapy, induced remissions in patients with relapsed/refractory CLL and SLL, including adverse-risk subsets of patients.

Obinutuzumab Regimen Slows CLL Compared With Rituximab

December 9th 2013

Patients with chronic lymphocytic leukemia and major comorbidities had significantly better outcomes when treated with the anti-CD20 monoclonal antibody obinutuzumab instead of rituximab.

Engineered T-Cells Achieve Dramatic Results in Resistant CLL

December 8th 2013

Treatment with engineered donor T cells led to substantial tumor regression in patients with posttransplant relapsed B-cell malignancies, results of a small clinical study showed.

Dr. Goede on Obinutuzumab Versus Rituximab in CLL

December 8th 2013

Valentin Goede, MD, from the University Hospital Cologne, discusses the efficacy findings from the stage 2 CLL11 study that examined obinutuzumab plus chlorambucil in patients with chronic lymphocytic leukemia with comorbidities.

Dr. Brown on Idelalisib Plus Rituximab in CLL

December 8th 2013

Jennifer Brown, MD, PhD, from the Dana-Farber Cancer Institute, discusses the development of the novel PI3K-delta inhibitor idelalisib as a treatment for patients with chronic lymphocytic leukemia.

Dr. Seymour on the Efficacy of ABT-199 in High-Risk CLL

December 8th 2013

John F. Seymour, MBBS, FRACP, PhD, discusses the efficacy of single-agent ABT-199 (GDC-0199), a novel Bcl-2 inhibitor, in high-risk relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

FDA Approves Frontline Obinutuzumab for CLL

November 1st 2013

The FDA has approved obinutuzumab plus chlorambucil as a first-line treatment for patients with chronic lymphocytic leukemia, based on clinical trial data demonstrating that the combination more than doubled median PFS over the chemotherapy agent alone.

Novel B-Cell Receptor Signaling Inhibitors Show Promise

October 23rd 2013

Drugs targeting B-cell receptor signaling pathways are improving outcomes for patients with B-cell lymphomas; these novel agents include idelalisib and ibrutinib, and are considered a breakthrough for CLL and other B-cell lymphomas.